|This article is an orphan, as no other articles link to it. Please introduce links to this page from ; try the Find link tool for suggestions. (September 2010)|
|Target||αβ T Cell Receptor|
Orphan drug status
TOL101 was granted "orphan drug" status  by the U.S. Food and Drug Administration for the treatment of recent onset immune-mediated Type 1 diabetes and for prophylaxis of acute rejection of solid organ transplantation.
Rationale for development
There are numerous agents currently under investigation that are capable of modulating T cells. Currently used agents include anti-thymocyte globulin(ATG) and alemtuzumab, which not only affect T cells, but are also capable of modulating many other aspects of the immune system, often resulting in long-term broad spectrum immune suppression. Antibodies specific for CD3 such as teplizumab and otelixizumab show increased specificity for T cells compared to ATG and alemtuzumab, but are still associated with infection and cytokine release syndrome. Targeting the αβ T cells with TOL101 may reduce these issues through two mechanisms. First, infections are expected[by whom?] to be reduced through the preservation of γδ T cells, which have been shown to play an important role in controlling viruses such as cytomegalovirus (CMV), often observed in antibody treated patients. Second, reductions in cytokine release are expected[by whom?] when targeting the αβ TCR because, unlike CD3 proteins, the αβ TCR contains none of the immunoreceptor tyrosine-based activation motifs (ITAMS) required for T cell activation.
Mechanism of action
TOL101 modulates αβ T cells
TOL101 has been shown in in vitro models to specifically modulate αβ T cells. Incubation of peripheral blood monocytes (PBMC) with TOL101 triggers rapid down modulation of the T cell receptor.[verification needed] Importantly, this occurs without T cell proliferation or cytokine induction. Examination of the ability of TOL101 to modulate T cells in a humanized mouse model not only confirmed these in vitro results but also suggested that the T cell modulating capability of the drug occurred in a non-depletional fashion.
αβ T cells antibodies in experimental disease models
Targeting αβ T cells with antibodies has been tested in numerous experimental models of disease. The data suggest that in models of multiple sclerosis (Experimental autoimmune encephalomyelitis) and type 1 diabetes (Non-obese diabetic mice,) anti-αβ TCR antibody therapy can ameliorate disease symptoms and progression.[verification needed] The precise mechanism through which this occurs remains to be defined, however, it is likely to involve the induction of operational tolerance.
TOL101 is a murine IgM antibody.
- Brennan, DC, Daller JA, Lake KD, Cibrik D, Del Castillo D (2006). "Rabbit antithymocyte globulin versus basiliximab in renal transplantation". N Engl J Med. 355 (19): 1967–77. PMID 17093248. doi:10.1056/NEJMoa060068.
- Mohty M (2007). "Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond". Leukemia. 21 (7): 1387–94. PMID 17410187. doi:10.1038/sj.leu.2404683.
- Chatenoud L (2010). "Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies?". Nature Reviews Endocrinology. 6 (3): 149–157. PMID 20173776. doi:10.1038/nrendo.2009.275.
- Beetz S, Wesch D, Marischen L, Welte S, Oberg HH, Kabelitz D (2008). "Innate immune functions of human gammadelta T cells". Immunobiology. 213 (3–4): 173–82. PMID 18406365. doi:10.1016/j.imbio.2007.10.006.
- Lafarge X, Merville P, Cazin MC, Berge F, Potaux L, Moreau JF, Dechanet-Merville J (2001). "Cytomegalovirus infection in transplant recipients resolves when circulating gammadelta T lymphocytes expand, suggesting a protective antiviral role". J Infect Dis. 184 (5): 533–41. PMID 11494158. doi:10.1086/322843.
- Getts DR, Brown S, Siemionow M, Miller, SD. "TOL101; a new aid to prevent allograft rejection". American Journal of Transplantation. 9 (Suppl 2): 991–766, LB26.
- Getts DR, Martin A, Siemionow M, Miller SD. "Operational tolerance vs immune suppression, targeting the αβ TCR with TOL101". American Journal of Transplantation. 10 (Suppl 4 1–608, LB07).
- Lavasani S, Dzhambazov B, et al. (2007). "Monoclonal antibody against T-cell receptor alphabeta induces self-tolerance in chronic experimental autoimmune encephalomyelitis". Scandinavian Journal of Immunology. 65 (1): 39–47. PMID 17212765. doi:10.1111/j.1365-3083.2006.01866.x.
- Sempe P, et al. (1991). "Anti-alpha/beta T cell receptor monoclonal antibody provides an efficient therapy for autoimmune diabetes in non-obese diabetic (NOD) mice". Eur J Immunol. 21 (5): 1163–9. PMID 1828030. doi:10.1002/eji.1830210511.